Literature DB >> 22732722

Effects of 18-kDa translocator protein knockdown on gene expression of glutamate receptors, transporters, and metabolism, and on cell viability affected by glutamate.

Leo Veenman1, Julia Bode, Michal Gaitner, Beatriz Caballero, Yelena Peʼer, Sivan Zeno, Silke Kietz, Wilfried Kugler, Max Lakomek, Moshe Gavish.   

Abstract

OBJECTIVE: Previously, several important roles for glutamate have been described for the biology of primary brain tumors. For example, glutamate has been suggested to promote glioma cell proliferation by the activation of the 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid (AMPA) subtype of glutamate receptors. In the present study, we determined the potential regulatory roles of the 18-kDa translocator protein (TSPO) in the glutamatergic system in relation to cell death of brain tumor cells through knockdown of the TSPO by genetic manipulation.
MATERIALS AND METHODS: With microarray analysis and validation of gene expression of particular genes using real-time PCR, we found effects because of small inhibitory RNA knockdown of the TSPO in human U118MG glioblastoma cells on gene expression of glutamate receptors, glutamate transporters, and enzymes for glutamate metabolism. We also applied antisense RNA to silence TSPO in rat C6 glioblastoma cells and assayed the effects on DNA fragmentation, indicative of apoptosis, because of glutamate exposure.
RESULTS: In particular, the effects of TSPO silencing in human U118MG cells related to glutamate metabolism indicate a net effect of a reduction in glutamate levels, which may potentially protect the cells in question from cell death. The TSPO knockdown in C6 cells showed that TSPO is required for the induction of apoptosis because of glutamate exposure.
CONCLUSION: These findings show that interactions between the TSPO and the glutamatergic system may play a role in tumor development of glioblastoma cells. This may also have implications for our understanding of the involvement of the TSPO in secondary brain damage and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22732722     DOI: 10.1097/FPC.0b013e3283544531

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  10 in total

1.  HCMV induces dysregulation of glutamate uptake and transporter expression in human fetal astrocytes.

Authors:  Li Zhang; Ling Li; Bin Wang; Dong-Meng Qian; Xu-Xia Song; Ming Hu
Journal:  Neurochem Res       Date:  2014-10-08       Impact factor: 3.996

2.  In vitro catabolic effect of protoporphyrin IX in human osteoblast-like cells: possible role of the 18 kDa mitochondrial translocator protein.

Authors:  Nahum Rosenberg; Orit Rosenberg; Abraham Weizman; Leo Veenman; Moshe Gavish
Journal:  J Bioenerg Biomembr       Date:  2013-03-09       Impact factor: 2.945

Review 3.  Researching glutamate - induced cytotoxicity in different cell lines: a comparative/collective analysis/study.

Authors:  Aristeidis A Kritis; Eleni G Stamoula; Krystallenia A Paniskaki; Theofanis D Vavilis
Journal:  Front Cell Neurosci       Date:  2015-03-17       Impact factor: 5.505

4.  Coordinated gene expression of neuroinflammatory and cell signaling markers in dorsolateral prefrontal cortex during human brain development and aging.

Authors:  Christopher T Primiani; Veronica H Ryan; Jagadeesh S Rao; Margaret C Cam; Kwangmi Ahn; Hiren R Modi; Stanley I Rapoport
Journal:  PLoS One       Date:  2014-10-20       Impact factor: 3.240

Review 5.  Tetrapyrroles as Endogenous TSPO Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic Ligands.

Authors:  Leo Veenman; Alex Vainshtein; Nasra Yasin; Maya Azrad; Moshe Gavish
Journal:  Int J Mol Sci       Date:  2016-06-04       Impact factor: 5.923

6.  Quinazoline-based tricyclic compounds that regulate programmed cell death, induce neuronal differentiation, and are curative in animal models for excitotoxicity and hereditary brain disease.

Authors:  A Vainshtein; L Veenman; A Shterenberg; S Singh; A Masarwa; B Dutta; B Island; E Tsoglin; E Levin; S Leschiner; I Maniv; L Pe'er; I Otradnov; S Zubedat; S Aga-Mizrachi; A Weizman; A Avital; I Marek; M Gavish
Journal:  Cell Death Discov       Date:  2015-11-30

7.  Classical and Novel TSPO Ligands for the Mitochondrial TSPO Can Modulate Nuclear Gene Expression: Implications for Mitochondrial Retrograde Signaling.

Authors:  Nasra Yasin; Leo Veenman; Sukhdev Singh; Maya Azrad; Julia Bode; Alex Vainshtein; Beatriz Caballero; Ilan Marek; Moshe Gavish
Journal:  Int J Mol Sci       Date:  2017-04-07       Impact factor: 5.923

Review 8.  Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update.

Authors:  Jasmina Dimitrova-Shumkovska; Ljupcho Krstanoski; Leo Veenman
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

9.  14,15-Epoxyeicosatrienoic Acid Protect Against Glucose Deprivation and Reperfusion-Induced Cerebral Microvascular Endothelial Cells Injury by Modulating Mitochondrial Autophagy via SIRT1/FOXO3a Signaling Pathway and TSPO Protein.

Authors:  Youyang Qu; Jinlu Cao; Di Wang; Shu Wang; Yujie Li; Yulan Zhu
Journal:  Front Cell Neurosci       Date:  2022-04-26       Impact factor: 6.147

10.  The TSPO Ligands 2-Cl-MGV-1, MGV-1, and PK11195 Differentially Suppress the Inflammatory Response of BV-2 Microglial Cell to LPS.

Authors:  Maya Azrad; Nidal Zeineh; Abraham Weizman; Leo Veenman; Moshe Gavish
Journal:  Int J Mol Sci       Date:  2019-01-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.